232 related articles for article (PubMed ID: 8300199)
1. Human antibody response to Clostridium difficile toxin A in relation to clinical course of infection.
Warny M; Vaerman JP; Avesani V; Delmée M
Infect Immun; 1994 Feb; 62(2):384-9. PubMed ID: 8300199
[TBL] [Abstract][Full Text] [Related]
2. Association between IgG2 and IgG3 subclass responses to toxin A and recurrent Clostridium difficile-associated disease.
Katchar K; Taylor CP; Tummala S; Chen X; Sheikh J; Kelly CP
Clin Gastroenterol Hepatol; 2007 Jun; 5(6):707-13. PubMed ID: 17544998
[TBL] [Abstract][Full Text] [Related]
3. Association of interleukin-8 polymorphism and immunoglobulin G anti-toxin A in patients with Clostridium difficile-associated diarrhea.
Jiang ZD; Garey KW; Price M; Graham G; Okhuysen P; Dao-Tran T; LaRocco M; DuPont HL
Clin Gastroenterol Hepatol; 2007 Aug; 5(8):964-8. PubMed ID: 17618838
[TBL] [Abstract][Full Text] [Related]
4. IgG antibody response to toxins A and B in patients with Clostridium difficile infection.
Wullt M; Norén T; Ljungh A; Åkerlund T
Clin Vaccine Immunol; 2012 Sep; 19(9):1552-4. PubMed ID: 22787196
[TBL] [Abstract][Full Text] [Related]
5. Circulating antibody and memory B-Cell responses to C. difficile toxins A and B in patients with C. difficile-associated diarrhoea, inflammatory bowel disease and cystic fibrosis.
Monaghan TM; Robins A; Knox A; Sewell HF; Mahida YR
PLoS One; 2013; 8(9):e74452. PubMed ID: 24058568
[TBL] [Abstract][Full Text] [Related]
6. Serum antibody response to toxins A and B of Clostridium difficile.
Viscidi R; Laughon BE; Yolken R; Bo-Linn P; Moench T; Ryder RW; Bartlett JG
J Infect Dis; 1983 Jul; 148(1):93-100. PubMed ID: 6886489
[TBL] [Abstract][Full Text] [Related]
7. Toxin-specific antibodies for the treatment of Clostridium difficile: current status and future perspectives.
Hussack G; Tanha J
Toxins (Basel); 2010 May; 2(5):998-1018. PubMed ID: 22069622
[TBL] [Abstract][Full Text] [Related]
8. Systemic and mucosal antibody responses to toxin A in patients infected with Clostridium difficile.
Johnson S; Gerding DN; Janoff EN
J Infect Dis; 1992 Dec; 166(6):1287-94. PubMed ID: 1431247
[TBL] [Abstract][Full Text] [Related]
9. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A.
Kyne L; Warny M; Qamar A; Kelly CP
N Engl J Med; 2000 Feb; 342(6):390-7. PubMed ID: 10666429
[TBL] [Abstract][Full Text] [Related]
10. Immunoglobulin G directed against toxins A and B of Clostridium difficile in the general population and patients with antibiotic-associated diarrhea.
Bacon AE; Fekety R
Diagn Microbiol Infect Dis; 1994 Apr; 18(4):205-9. PubMed ID: 7924215
[TBL] [Abstract][Full Text] [Related]
11. Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI).
Leav BA; Blair B; Leney M; Knauber M; Reilly C; Lowy I; Gerding DN; Kelly CP; Katchar K; Baxter R; Ambrosino D; Molrine D
Vaccine; 2010 Jan; 28(4):965-9. PubMed ID: 19941990
[TBL] [Abstract][Full Text] [Related]
12. Clostridium difficile vaccine and serum immunoglobulin G antibody response to toxin A.
Aboudola S; Kotloff KL; Kyne L; Warny M; Kelly EC; Sougioultzis S; Giannasca PJ; Monath TP; Kelly CP
Infect Immun; 2003 Mar; 71(3):1608-10. PubMed ID: 12595488
[TBL] [Abstract][Full Text] [Related]
13. Development and evaluation of an ovine antibody-based platform for treatment of Clostridium difficile infection.
Roberts A; McGlashan J; Al-Abdulla I; Ling R; Denton H; Green S; Coxon R; Landon J; Shone C
Infect Immun; 2012 Feb; 80(2):875-82. PubMed ID: 22144483
[TBL] [Abstract][Full Text] [Related]
14. Correlation of disease severity with fecal toxin levels in patients with Clostridium difficile-associated diarrhea and distribution of PCR ribotypes and toxin yields in vitro of corresponding isolates.
Akerlund T; Svenungsson B; Lagergren A; Burman LG
J Clin Microbiol; 2006 Feb; 44(2):353-8. PubMed ID: 16455883
[TBL] [Abstract][Full Text] [Related]
15. Clostridium difficile carriage and serum antitoxin responses in children with inflammatory bowel disease.
Hourigan SK; Chirumamilla SR; Ross T; Golub JE; Rabizadeh S; Saeed SA; Elson CO; Kelly CP; Carroll KC; Oliva-Hemker M; Sears C
Inflamm Bowel Dis; 2013 Dec; 19(13):2744-52. PubMed ID: 24145927
[TBL] [Abstract][Full Text] [Related]
16. Induction of antitoxin responses in Clostridium-difficile-infected patients compared to healthy blood donors.
von Eichel-Streiber A; Paik W; Knight K; Gisch K; Nadjafi K; Decker C; Bosnjak O; Cheknis A; Johnson S; von Eichel-Streiber C
Anaerobe; 2016 Oct; 41():91-103. PubMed ID: 27427464
[TBL] [Abstract][Full Text] [Related]
17. Treatment with intravenously administered gamma globulin of chronic relapsing colitis induced by Clostridium difficile toxin.
Leung DY; Kelly CP; Boguniewicz M; Pothoulakis C; LaMont JT; Flores A
J Pediatr; 1991 Apr; 118(4 Pt 1):633-7. PubMed ID: 1901084
[TBL] [Abstract][Full Text] [Related]
18. Antibodies to recombinant Clostridium difficile toxins A and B are an effective treatment and prevent relapse of C. difficile-associated disease in a hamster model of infection.
Kink JA; Williams JA
Infect Immun; 1998 May; 66(5):2018-25. PubMed ID: 9573084
[TBL] [Abstract][Full Text] [Related]
19. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea.
Kyne L; Warny M; Qamar A; Kelly CP
Lancet; 2001 Jan; 357(9251):189-93. PubMed ID: 11213096
[TBL] [Abstract][Full Text] [Related]
20. Sensitive assays enable detection of serum IgG antibodies against Clostridium difficile toxin A and toxin B in healthy subjects and patients with Clostridium difficile infection.
Zhao X; Bender F; Shukla R; Kang JJ; Caro-Aguilar I; Laterza OF
Bioanalysis; 2016 Apr; 8(7):611-23. PubMed ID: 26964649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
